Fate Therapeutics (FATE) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
